Profusa, Inc.
PFSAHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeProfusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. The company carries a $508K market cap, placing it firmly in the micro-cap category. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery.
Market Cap
$508,198
Beta
0.50
P/E (TTM)
0.00
P/E (Fwd)
—
EPS (TTM)
$897.26
EPS (Fwd)
—
ROE
—
ROA
-725.3%
Cash
$719,000
Total Debt
$14.1M
Free CF
-$19.1M
52W Change
-100.0%
Annual Financials
Cash vs Debt
Where PFSA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PFSA finished 96.59% below its 150-day moving average ($26.39) and 99.29% below its 200-day moving average ($126.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PFSA overbought or oversold?
At the October 20, 2026 close, PFSA's RSI(14) was 4.0, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, PFSA has $719K in cash with $14.1M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$19.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
The relatively low beta of 0.50 suggests PFSA is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Profusa, Inc. and its sector.